Would rhapsido be beneficial in patients with MCAS who experience anaphylaxis?  

Remibrutinib is the first FDA-approved BTK inhibitor (BTKi). The efficacy data shared were specifically in patients with CSU who failed 4x antihistamine therapy. This class of medication holds promise and may be applicable to other conditions we treat, including anaphylaxis. I refer you to an intere...